Wendi Helsabeck
Family · Mount Airy, NCNPI 1992271209
Payments from drug & device makers
Across 100 payments — averaging $18.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$425
- Novo Nordisk$225
- Pfizer$185
- Sanofi-aventis U.S. LLC$119
- Axsome Therapeutics, Inc.$92
- Boehringer Ingelheim$79
- plus $728 from 21 others
What the payments were for
- Food & beverage$1,853100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 21 | $425 |
| Novo Nordisk | 14 | $225 |
| Pfizer | 10 | $185 |
| Sanofi-aventis U.S. LLC | 6 | $119 |
| Axsome Therapeutics, Inc. | 2 | $92 |
| Boehringer Ingelheim | 5 | $79 |
| Paratek Pharmaceuticals, Inc. | 5 | $73 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $67 |
| AbbVie | 3 | $64 |
| Lilly USA, LLC | 4 | $64 |
| Dexcom, Inc. | 2 | $51 |
| Viatris Specialty LLC | 2 | $41 |
| Astellas Pharma US Inc | 3 | $40 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $37 |
| Xeris Pharmaceuticals, Inc. | 2 | $37 |
| Phathom Pharmaceuticals, Inc. | 2 | $33 |
| Bayer | 2 | $29 |
| GSK | 2 | $27 |
| Mylan Specialty L.p. | 1 | $25 |
| Alkermes, Inc. | 1 | $23 |
| Verona Pharma, Inc. | 1 | $23 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
| Merck | 1 | $16 |
| Johnson & Johnson | 1 | $16 |
| Amgen | 1 | $15 |
| Exact Sciences | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $13 |
How this compares
$1,853 in reported general payments places this provider in the 80th percentile of 4,522 family providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 80 | $65,269 |
| FarxigaDapagliflozin Propanediol | 39 | $42,142 |
| JardianceEmpagliflozin | 20 | $35,299 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 34 | $22,904 |
| OzempicSemaglutide | 20 | $22,786 |
| JanuviaSitagliptin Phosphate | 17 | $21,896 |
| MounjaroTirzepatide | 12 | $15,094 |
| Spiriva RespimatTiotropium Bromide | 14 | $9,356 |
| LinzessLinaclotide | 15 | $8,456 |
| SymbicortBudesonide/Formoterol Fumarate | 29 | $6,954 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 15 | $5,980 |
| TrintellixVortioxetine Hydrobromide | 12 | $5,197 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $4,911 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $4,769 |
| Gabapentin | 199 | $3,956 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $425 | $72,000102 claims |
| PfizerEliquis | $185 | $65,26980 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $79 | $44,65534 claims |
| Novo NordiskOzempic | $225 | $22,78620 claims |
| MerckJanuvia | $16 | $21,89617 claims |
| Lilly USA, LLCMounjaro | $64 | $15,09412 claims |
| AbbVieLinzess, Synthroid | $64 | $9,45337 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $67 | $5,19712 claims |
| GSKIncruse Ellipta | $27 | $4,91112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,522 family providers in North Carolina.
Other family in Mount Airy
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Nicole RothmanDurham$268K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
- Juanita PerkinsDurham$213K
- Teresa DossWilmington$137K
- Debra ScottCharlotte$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.